Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
– Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO
– $125 million private placement investment completed with leading institutional investors will support cash runway expected to extend into Q1 2026*
– Expected to submit three investigational new drug applications (INDs) within 18 months